Quantcast

Latest Genzyme Stories

2014-07-03 12:26:08

STOCKHOLM, July 3, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, is very pleased to announce that Mrs Ann-Tove Kongsnes, Mrs Hilde Furberg and Mr Olav Hellebo were elected as new members of its Board of Directors at the Company's recent shareholders' meeting held in Stockholm. At the same meeting, Ms Elisabeth Lindner stepped down from the Board. Ann-Tove Kongsnes (born 1967) is an Investment Director at Investinor,...

2014-06-12 12:30:07

Current Neurologist-Reported Patient Share for Tecfidera Exceeds that of Genzyme's Aubagio and Novartis's Gilenya Combined, According to Findings from Decision Resources Group BURLINGTON, Mass., June 12, 2014 /PRNewswire/ -- Decision Resources Group finds that, within one year of commercial availability, 100 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their multiple sclerosis (MS) patients, far surpassing the one-year trial rate for...

2014-06-03 12:37:18

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Translational Regenerative Medicine: Market Prospects 2014-2024http://www.reportbuyer.com/pharma_healthcare/research_r_d/translational_regenerative_medicine_market_prospects_2012_2022.html Report DetailsOur new study shows you the commercial potential of regenerative treatmentsWhat does the future hold for regenerative medicine? Visiongain's brand new report shows you potential revenues to...

2014-05-15 12:29:33

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Markets for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/drug_discovery/global_markets_orphan_drugs.htmlINTRODUCTIONSTUDY OBJECTIVESThe orphan drug market is one of the fastest-growing segments in the pharmaceutical and biotechnology industry. BCC's goal in conducting this study is to provide an overview of the current and future global market for orphan drugs. The key...

2014-05-08 08:34:19

ROCKVILLE, Md., May 8, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced the appointment of Sandford Drexel Smith to its Board of Directors, bringing the total number of board members to seven, five of whom are independent. Mr. Smith is the former President, International Group, and Executive Vice President of Genzyme Corporation. He also served on Genzyme's Executive Committee, where he reported directly to the Chairman and CEO. As President of the International Group,...

2014-05-01 12:32:03

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies - - Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension - CAMBRIDGE, MA, May 1, 2014 /CNW/ - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada...

2014-04-29 08:36:15

PARIS, April 29, 2014 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2014 Change (reported) Change (CER) Net sales EUR7,842m -2.7% +3.5% Business net income(2) EUR1,547m -3.2% +5.6% Business EPS(1) EUR1.17 -3.3% +5.8% -------------- ------- ---- ---- In order to facilitate an understanding of our operational...

2014-04-29 04:21:53

PARIS, April 29, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first-quarter of 2014. Jerome Contamine, Chief Financial Officer of Sanofi, comments on results and R&D pipeline. Watch video interview and read transcript: http://www.eurobusinessmedia.com/ceo-direct/sanofi/interview-with-cfo-jerome-contamine-q1-2014-results,2014-04-28,1175?utm_source=ceo-direct&utm_medium=wire Topics covered in the...

2014-04-15 12:30:41

Market Access Challenges for Sanofi/Genzyme's Aubagio Highlight the Hurdles New Multiple Sclerosis Agents Face in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within...

2014-03-18 08:29:03

For MS Awareness Month, MSAA Launches Effort to Get More People with MS in the Pool CHERRY HILL, N.J., March 18, 2014 /PRNewswire/ -- In honor of Multiple Sclerosis (MS) Awareness Month, the Multiple Sclerosis Association of America (MSAA), through a collaborative partnership with Genzyme, a Sanofi company, is proud to announce the stories from three individuals in the MS community who describe how swimming has helped manage their MS symptoms and improve their overall well-being. Today, MSAA...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.